Impact of Sjögren's disease on quality of sexual life using the Qualisex score

Association between anti-SSA/SSB antibody profiles and patient-reported outcomes in primary Sjögren's disease

Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts

Immune Checkpoint Inhibitor-induced Sicca Syndrome

Obinutuzumab in patients with Sjogren's disease immunised against rituximab

Pregnancy outcomes in women with primary Sjögren's syndrome: an analysis of data from the multicentre, prospective, GR2 study

Efficacy of daratumumab in refractory primary Sjögren disease

Analysis of the dental care queries in the "Mouth-Nose" discussion forum of the French association of patients with Gougerot-Sjögren's syndromes and dryness

Normal salivary gland ultrasonography could rule out the diagnosis of Sjögren's syndrome in anti-SSA-negative patients with sicca syndrome

Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone

Usefulness of (18) F-Labeled Fluorodeoxyglucose-Positron Emission Tomography for the Diagnosis of Lymphoma in Primary Sjögren's Syndrome

Large granular lymphocyte expansions in primary Sjögren's syndrome: characteristics and outcomes

Brief Report: Monoclonal Gammopathy and Risk of Lymphoma and Multiple Myeloma in Patients With Primary Sjögren's Syndrome

Overlap between differentially methylated DNA regions in blood B lymphocytes and genetic at-risk loci in primary Sjögren's syndrome

CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome

Low numbers of blood and salivary natural killer cells are associated with a better response to belimumab in primary Sjögren's syndrome: results of the BELISS study

ACPA-positive primary Sjögren's syndrome: true primary or rheumatoid arthritis-associated Sjögren's syndrome?

Upregulation of membrane-bound CD40L on CD4+ T cells in women with primary Sjögren's syndrome

Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort

Immune checkpoint inhibitor-induced joint involvement

Evaluation of pregnancy outcomes in patients with spondyloarthritis compared to the general population: results from a French national prospective and matched study

Immune checkpoint inhibitors-associated vasculitis: a heterogeneous condition with possible severe disease course

Sicca induced by immune checkpoint inhibitors

[Osteoporosis: Why, when and how to treat? How can it be prevented?]

Molecular profiling and risk stratification in solitary bone plasmacytoma

High rate of progression to symptomatic multiple myeloma in patients with smoldering myeloma and isolated osteoporotic vertebral fracture

Clonal CD8(+) T-cell expansion is associated with complete response to elranatamab in refractory multiple myeloma

Chemotherapy in solitary bone plasmacytoma to prevent evolution to multiple myeloma

Features of polymyalgia rheumatica-like syndrome after immune checkpoint inhibitor therapy

Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study

Lack of association between the TNFAIP3 rs2230926 variant and rheumatoid arthritis-associated lymphoma

Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls

Lymphoma complicating rheumatoid arthritis: results from a French case-control study

The 2016-2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment

Obinutuzumab in patients with Sjogren's disease immunised against rituximab

Rituximab Impairs B Cell Response But Not T Cell Response to COVID-19 Vaccine in Autoimmune Diseases

Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses

Peripheral ulcerative keratitis in rheumatoid arthritis patients taking tocilizumab: paradoxical manifestation or insufficient efficacy?

Efficacity of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone

Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: ofatumumab as alternative therapy

Doses of rituximab for retreatment in rheumatoid arthritis: influence on maintenance and risk of serious infection

Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease

Teclistamab in relapsed refractory multiple myeloma: a multi-institutional real-world study from the French early access program

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study

Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort

Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report

Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial

Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease

Iron Supplementation-Induced Phosphaturic Osteomalacia: FGF23 is the Culprit

Denosumab in active Charcot neuro-osteoarthropathy of the foot

Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study

Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases